Chronic wounds, including diabetic foot ulcers, venous ulcers, and pressure ulcers, pose significant healthcare challenges and require specialized management to facilitate healing and prevent ...

VVeno Medical Corporation ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap ...

Consultant vascular surgeon Ian Nichol, who works at The James Cook University Hospital, saved the leg of Chris Dolan, 50 ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

A new federal payment policy will sharply reduce the number of specialty wound care products available to certain Medicare patients.

The global tissue engineered skin substitute market is projected to grow from USD 2.4 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 3.9%. The rising demand for advanced wound care solutions ...

Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% ...

With revyve, we could address wounds early in the treatment continuum, greatly broadening the patient population BioStem supports and offering multiple opportunities for channel expansion. We believe ...

BioStem expects to finalize definitive agreements within 60 days following customary due diligence. The transaction is subject to regulatory approvals and Board consent. BioStem and ProgenaCare will ...

November 20, 2024—enVVeno Medical Corporation announced 1-year data on all patients from SAVVE, the United States pivotal trial of the company&r ...

Chronic wounds, particularly those caused by diabetes and venous leg ulcers, account for the largest share of demand ... As ...